A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer

IF 0.3 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Clinical and Experimental Health Sciences Pub Date : 2023-09-26 DOI:10.33808/clinexphealthsci.1345763
Alev BAKIR KAYI, Benan MÜSELLİM
{"title":"A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer","authors":"Alev BAKIR KAYI, Benan MÜSELLİM","doi":"10.33808/clinexphealthsci.1345763","DOIUrl":null,"url":null,"abstract":"Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival.
 Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations' Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included.
 Results: Out of 247 non-small cell lung cancer (NSCLC) cases analysis, 220 (89%) were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of “diabetes and interstitial lung disease” and 3.76 for “diabetes and previously cancer”. Existing comorbid indices had no significant effect on survival time (p:0.684; 0.101; 0.273; 0.567, respectively).
 Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.","PeriodicalId":10192,"journal":{"name":"Clinical and Experimental Health Sciences","volume":"138 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33808/clinexphealthsci.1345763","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Mortality studies are interpreted by considering comorbid diseases related to the main disease. Existence, number, and type of comorbid diseases can have an important effect on prognosis. There are various comorbidity indices to include the effects of comorbid diseases in the model. With a new perspective, we aimed to emphasize the importance of evaluating the combination of comorbid diseases in cancer survival. Methods: Retrospective cohort, data were collected from cases with Non-Small Cell Lung Cancer treated in Department of Chest Diseases. Initially, the effects of their comorbid diseases on the duration of survival were calculated with univariate analysis, then examined according to number of comorbidities, lastly their specific combinations' Hazar Ratio were calculated with Cox multivariate analysis. The most used comorbid indices in the literature were also included. Results: Out of 247 non-small cell lung cancer (NSCLC) cases analysis, 220 (89%) were men. Median duration of follow-up was 277 days, at the end of the follow-up 197 cases had died. HR of two comorbid diseases in cases was 1.80, but 59.52 for the combination of “diabetes and interstitial lung disease” and 3.76 for “diabetes and previously cancer”. Existing comorbid indices had no significant effect on survival time (p:0.684; 0.101; 0.273; 0.567, respectively). Conclusion: We have offered a new perspective which takes into comorbid diseases related to main disease and specially their combinations when the risk is estimated in survival research. Accurate assessments of the list of comorbid diseases related to main disease hold significant importance in advancing this field.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非小细胞肺癌共病指标评价的新视角
目的:通过考虑与主要疾病相关的合并症来解释死亡率研究。合并症的存在、数量和类型对预后有重要影响。在模型中有各种共病指数来包括共病疾病的影响。从一个新的角度,我们旨在强调评估合并症在癌症生存中的重要性。 方法:回顾性分析胸科收治的非小细胞肺癌患者资料。首先用单因素分析计算其合并症对生存时间的影响,然后根据合并症的数量进行检查,最后用Cox多因素分析计算其特定组合的危险比。文献中最常用的合并症指标也包括在内。 结果:在247例非小细胞肺癌(NSCLC)病例中,220例(89%)为男性。中位随访时间为277天,随访结束时死亡197例。两种疾病合并症的HR为1.80,“糖尿病合并间质性肺疾病”的HR为59.52,“糖尿病合并既往癌症”的HR为3.76。现有合并症指标对生存时间无显著影响(p:0.684;0.101;0.273;分别为0.567)强生# x0D;结论:在生存研究中评估风险时,考虑与主要疾病相关的合并症,特别是它们的联合,提供了一个新的视角。准确评估与主要疾病相关的共病清单对推进这一领域具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical and Experimental Health Sciences
Clinical and Experimental Health Sciences MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
73
期刊最新文献
Percutaneous Cholecystostomy is a Feasible and Safe Option for High-Risk Acute Cholecystitis Patients A New Perspective on the Evaluation of Comorbidity Indices on Survival in Non-Small Cell Lung Cancer Radiographic Evaluation of the Effect of Vitamin D3 Supplementation on Regeneration of Calvarial Bone Defects in Rats Awareness of the Protective Measures Against Covid-19 among Turkish Dentists: A Questionnaire Survey Otoprotective Mechanisms of Carvone As An Antioxidant Agent Against Ototoxic Damage Caused By Paclitaxel
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1